Business Context and Reporting Period
This Form 8-K is a current report filed by NeuroBo Pharmaceuticals, Inc. (not Metavia Inc.) on August 30, 2020, regarding events occurring on August 30 and September 1, 2020. The registrant is a Delaware corporation with principal executive offices in Boston, Massachusetts, and its common stock trades on The Nasdaq Stock Market under the symbol NRBO. The company is classified as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
- Board Departure: Steven Gullans, Ph.D., resigned from the Board of Directors effective August 31, 2020. The resignation was not the result of any disagreement with the Company regarding operations, policies, or practices.
- Board Appointment: Douglas J. Swirsky was appointed as a Class I member of the Board on September 1, 2020, to fill the vacancy. Mr. Swirsky currently serves as President and CEO of Rexahn Pharmaceuticals, Inc. and Chairman of the Board of Cellectar Biosciences, Inc.
- Committee Assignment: Mr. Swirsky was appointed to the Audit Committee of the Board.
Compensation and Governance Details
Mr. Swirsky's compensation includes cash compensation of $20,000 per year for Board service, plus an additional $20,000 per year for service on at least one Board committee. He also received an option to purchase 60,000 shares of the Company's common stock, vesting monthly over three years, subject to continuing service. No transactions requiring disclosure under Item 404(a) of Regulation S-K were identified.
Investor Verification Checklist
- Verify the press release dated September 2, 2020 (Exhibit 99.1) for additional context on the board changes.
- Confirm Douglas J. Swirsky's current roles at Rexahn Pharmaceuticals and Cellectar Biosciences to assess potential conflicts of interest or time commitments.
- Review the Company's proxy statement or subsequent filings for details on the full Board composition and Audit Committee qualifications.
- Note that this filing contains no financial data; refer to the most recent 10-Q or 10-K for financial metrics.